The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination with bevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectal cancer (CRC): AIO KRK 0205.
G. von Wichert
No relevant relationships to disclose
T. Hoehler
No relevant relationships to disclose
C. C. Schimanski
No relevant relationships to disclose
M. H. Moehler
Consultant or Advisory Role - Roche; Sanofi
R. Hofheinz
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
S. Kanzler
No relevant relationships to disclose
A. Hinke
No relevant relationships to disclose
T. Seufferlein
No relevant relationships to disclose
J. Siebler
No relevant relationships to disclose
A. Hochhaus
No relevant relationships to disclose
D. Arnold
Consultant or Advisory Role - Roche
Honoraria - Roche
M. Hallek
No relevant relationships to disclose
U. T. Hacker
Honoraria - Novartis